Inclusion Criteria:

          -  All patients and/or their parents or legal guardians must have the ability to
             understand and the willingness to sign a written informed consent

          -  Voluntary written informed consent must be obtained before performance of any
             study-related procedure not part of normal medical care, with the understanding that
             consent may be withdrawn by the subject at any time without prejudice to future
             medical care

          -  Weight over 40 kg

          -  Life expectancy of greater than 3 months

          -  Patients must have histologically documented or cytologically confirmed Hodgkin
             lymphoma

          -  Patient must have measurable disease > 1.5 cm evidenced by computed tomography (CT) of
             the neck/chest/abdomen (abd)/pelvis or CT/positron emission tomography (PET) scans

          -  Be willing to provide tissue from a fresh core or excisional biopsy (performed as
             standard of care) of a tumor lesion prior to starting study therapy or from archival
             tissue of a biopsy that was performed after the most recent systemic therapy.
             Exception can be granted by the principal investigator (PI) if a biopsy is not
             feasible and/or safe

          -  Patients must be either refractory to or relapsed after at least 1 line of therapy

          -  Prior brentuximab vedotin is allowed; expansion cohort is defined as:

               -  Expansion cohort: BV refractory: Patient who had prior exposure to BV, and either
                  - achieved a best response of stable disease (SD) or progressive disease (PD) or
                  - achieved a best response of complete response (CR)/PR but developed PD while on
                  active BV treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0-2

          -  Prior chemotherapy or radiation therapy is allowed if received >= 3 weeks before study
             enrollment

          -  Prior hematopoietic transplantation is allowed (autologous and/or allogeneic)

          -  Absolute neutrophil count (ANC) >= 1,000/mm^3; filgrastim can be given prior to
             enrollment to achieve target ANC >= 1000/uL (to be performed within 10 business days
             prior to day 1)

          -  Platelets >= 50,000/mm^3; NOTE: platelet transfusion and packet red blood cell
             transfusion can be given prior to enrollment to achieve a target platelet (Plt) >=
             50,000/uL and hemoglobin of >= 8.5 g/dL (to be performed within 10 business days prior
             to day 1)

          -  Hemoglobin >= 8.5 g/dL (to be performed within 10 business days prior to day 1)

          -  Total bilirubin within 1.5 x the upper limit of normal institutional limits; patients
             with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
             (to be performed within 10 business days prior to day 1)

          -  Aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless
             demonstrated Hodgkin lymphoma involvement of the liver (to be performed within 10
             business days prior to day 1)

          -  Alanine aminotransferase (ALT) =< 3 x ULN unless demonstrated Hodgkin lymphoma
             involvement of the liver (to be performed within 10 business days prior to day 1)

          -  Creatinine clearance of >= 50 mL/min per the Cockcroft-Gault formula and/or 24 hour
             (hr) urine analysis as needed (to be performed within 10 business days prior to day 1)

          -  If not receiving anticoagulants: international normalization ratio (INR) OR
             prothrombin (PT) =< 1.5 x ULN; if on anticoagulant therapy: PT must be within
             therapeutic range of intended use of anticoagulants (to be performed within 10
             business days prior to day 1)

          -  If not receiving anticoagulants: activated partial thromboplastin time (aPTT) =< 1.5 x
             ULN; if on anticoagulant therapy: aPTT must be within therapeutic range of intended
             use of anticoagulants (to be performed within 10 business days prior to day 1)

          -  Female of childbearing potential: negative urine or serum pregnancy test; if the urine
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be
             required (to be performed within 10 business days prior to day 1)

          -  In patients who are to receive VRP, base systolic blood pressure (SBP) > 110;
             diastolic blood pressure (DBP) > 60 and baseline heart rate > 60 (to be performed
             within 10 business days prior to day 1)

          -  Cardiac function (12 lead-electrocardiogram [ECG] versus [vs] non 12 led ECG) shows no
             underlying arrhythmia or heart blocks (for VRP only) (to be performed within 10
             business days prior to day 1)

          -  Female subjects must be either post-menopausal, surgically sterilized, or willing to
             use an acceptable method of birth control (i.e. a hormonal contraceptive,
             intra-uterine deice, diaphragm with spermicide, condom with spermicide, or abstinence)
             beginning prior to study entry, for the duration of the study, and for six months
             duration of study participation; should a woman become pregnant or suspect that she is
             pregnant while participating on the trial, she should inform her treating physician
             immediately

          -  Male subjects must agree to use an acceptable method of contraception beginning prior
             to study entry, for the duration of the study, and for six months following duration
             of study participation

        Exclusion Criteria:

          -  Patients who are hematopoietic stem cell transplant candidates are excluded

          -  Vaccinated with live, attenuated vaccines within 4 weeks of enrollment

          -  Patients may be on steroids prior to initiation of treatment, provided that, by cycle
             1 day 1, steroid use is tapered down to less than or equal to 20 mg/day of prednisone

          -  Patients may not be receiving any other investigational agents, or concurrent
             biological therapy, chemotherapy, or radiation therapy

          -  Active graft versus host disease (GVHD) or on immunosuppressive medication of GVHD

          -  Recent infection requiring intravenous anti-infective treatment that was completed =<
             14 days before enrollment

          -  Unresolved toxicities from prior anticancer therapy, defined as having resolved to
             Common Terminology Criteria for Adverse Events (CTCAE, version 4.03), grade 0 or 1,
             with the exception of alopecia

          -  Baseline grade II peripheral neuropathy

          -  Hypersensitivity to BV or history of allergic reaction attributed to compounds of
             similar chemical or biologic composition of BV

          -  Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
             gastrointestinal function, or resection of the stomach or small bowel, symptomatic
             inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
             obstruction

          -  Patients should not have any uncontrolled illness including ongoing or active
             infection

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the investigator's opinion, could compromise the subject's safety or put the study
             outcomes at undue risk

          -  Myocardial infarction within 6 months prior to enrollment or New York Heart
             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior to study entry, any ECG
             abnormality at screening has to be documented by the investigator as not medically
             relevant

          -  Significant screening electrocardiogram (ECG) abnormalities including, but not limited
             to, left bundle branch block, 2nd degree atrioventricular (AV) block type II, 3rd
             degree block, or corrected QT interval (QTc) >= 470 msec; subjects with a cardiac
             pacemaker who have a QTc interval of >= 470 msec may be eligible if these findings are
             considered not clinically significant as documented via a cardiology evaluation

          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

          -  Patients with active central nervous system (CNS) disease or history of brain
             metastases are excluded from study

          -  Known active human immunodeficiency virus (HIV) or hepatitis C virus (HCV) or
             hepatitis B virus (HBV) infection; subjects who have an undetectable HIV viral load
             with CD4 >= 200 and are on highly active antiretroviral therapy (HAART) medication are
             allowed; subjects who are positive for hepatitis B core antibody or hepatitis B
             surface antigen must have a negative polymerase chain reaction (PCR) result before
             enrollment; those who are PCR positive will be excluded; patients who have had
             hepatitis C but have finished treatment and are PCR negative will be allowed; (testing
             to be done only in patients suspected of having infections or exposures)

          -  Pregnant women are excluded from this study because of the potential for teratogenic
             or abortifacient effects; because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother, breastfeeding should
             be discontinued

          -  Any other condition that would, in the investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns with clinical
             study procedures

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)

          -  Unable to understand the purpose and risks of the study and to provide a signed and
             dated informed consent form (ICF) and authorization to use protected health
             information (in accordance with national and local subject privacy regulations)